Everything below concerns lyophilisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
| Property | Value | Notes |
|---|---|---|
| Solid storage temperature | -20 °C or below | Desiccated and protected from light |
| Solution storage temperature | -80 °C as single-use aliquots | Avoid repeated freeze-thaw cycles |
| Purity assessment method | RP-HPLC, around 214 nm | Reported as main-peak area percent |
| Identity confirmation method | ESI-MS or MALDI-TOF | Measured mass compared with calculated mass |
| Common synonyms | ACTH(4-10) analog; Met-Glu-His-Phe-Pro-Gly-Pro | Also written as Semaxum in some sources |
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
各国监管态度分化明显。俄罗斯按处方药管理，部分东欧国家留有使用记录；欧盟与美国未批准其作为药物上市，市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录，跨境携带则受目的地药品法规约束。
Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
DIPG is a terminal illness, since it has a 5-year survival rate of <1%. The median overall survival of children diagnosed with DIPG is approximately 9 months. The 1- and 2-year survival rates are approximately 30% and less than 10%, respectively. These statistics make DIPG one of the most devastating pediatric cancers. Although 75–85% of patients show some improvement in their symptoms after radiation therapy, DIPGs almost always begin to grow again (called recurrence, relapse, or progression). Clinical trials have reported that the median time between radiation therapy and progression is 5–8.8 months. Patients whose tumors begin to grow again may be eligible for experimental treatment through clinical trials to try to slow or stop the growth of the tumor. However, clinical trials have not shown any significant benefit from experimental DIPG therapies so far. For DIPGs that progress, they usually grow quickly and affect important parts of the brain. The median time from tumor progression to death is usually very short, between 1 and 4.5 months. During this time, doctors focus on palliative care: controlling symptoms and making the patient as comfortable as possible.
== Summary == Strauss, a novelist, recounts how his life was profoundly altered when a car he was driving struck and killed a high school classmate. She was on a bicycle that swerved in front of his car. Although it was determined Strauss could in no way have avoided the accident, the book details his attempts, over half his life, to come to terms with his feelings of responsibility.
=== Research === A major thread of Bumpus' research is determining how antiviral drugs used to treat HIV-1 are metabolized and how genetic variations in drug-processing enzymes may impact these drugs' efficacy. One antiviral commonly used to treat and prevent HIV is tenofovir (Viread). Tenofovir is a nucleotide analog reverse transcriptase inhibitor that prevents the HIV virus from replicating. Tenofovir is given in an inactive form – it has to be phosphorylated twice to become active, and this phosphorylation is carried out in two steps by separate kinases. Bumpus and her team identified which kinases do this and found that the enzymes responsible varied by cell type, so administration route (e.g. orally or topically) could affect how effectively the drug is processed. They also sequenced the genes of these kinases from different patients and found that some people have genetic variants in the kinases that may affect how effectively the drug is processed. Tenofovir can be given prophylactically, and Bumpus collaborated with researchers from around the world in a study of the use of tenofovir for HIV pre-exposure prophylaxis (PrEP) to prevent HIV infection in heterosexual men and women. Bumpus has also researched nonnucleoside reverse transcriptase inhibitors. Her lab was the first to publish the P450-catalyzed phase 1 and phase 2 metabolic pathways of two nonnucleoside reverse transcriptase inhibitors, rilpivirine and etravirine and was first to characterize the metabolism of the nonnucleoside reverse transcriptase inhibitor dapivirine.
Sources: en.wikipedia.org
In most cases the proton-motive force is generated by an electron transport chain which acts as a proton pump, using the Gibbs free energy of redox reactions to pump protons (hydrogen ions) out across the membrane, separating the charge across the membrane. In mitochondria, energy released by the electron transport chain is used to move protons from the mitochondrial matrix (N side) to the intermembrane space (P side). Moving the protons out of the mitochondrion creates a lower concentration of positively charged protons inside it, resulting in excess negative charge on the inside of the membrane. The electrical potential gradient is about -170 mV , negative inside (N). These gradients - charge difference and the proton concentration difference both create a combined electrochemical gradient across the membrane, often expressed as the proton-motive force (PMF). In mitochondria, the PMF is almost entirely made up of the electrical component but in chloroplasts the PMF is made up mostly of the pH gradient because the charge of protons H+ is neutralized by the movement of Cl− and other anions. In either case, the PMF needs to be greater than about 460 mV (45 kJ/mol) for the ATP synthase to be able to make ATP.
=== Nordic countries === Norway was the first country in the world to outlaw beak trimming in 1974, followed by Finland in 1986 and Sweden in 1988. Beak trimming was subsequently phased out in Denmark in two stages: in 2013 for the enriched cage system and in 2014 for aviary and free range systems.
On September 28 Hanmi and Zentec Pharmaceuticals agreed that Zentec would market Hanmi's small molecule cancer drug candidate, HM95573; Zentec paid $80 million upfront, with $830 million in milestones, and royalties. On September 29, Hanmi and Roche's cancer subsidiary Genentech announced a deal for Hanmi's Phase I cancer drug candidate, HM95573, which targets the MAPK/ERK pathway; Roche agreed to pay $80 million upfront, and the deal included $830 million in milestones. In December 2016 the Sanofi deal was reduced in scope, with Hanmi receiving back rights to the once-weekly insulin and the combination GLP1-RA/insulin product, and agreeing to repay Sanofi $250 million of the $434 million upfront payment. On December 3, 2019, Rapt Therapeutics and Hanami Pharmaceutical announced collaboration to develop and commercialize FLX475 in Asia. FLX475 is an oral, small molecule CCR4 antagonist in development for the treatment of multiple cancers. In August 2020, chairman and founder of Hanmi Pharmaceutical Lim Sung-ki died of a chronic disease. He was 80. On May 15, 2023, Athenex, which was Hanmi's U.S. partner for its anticancer product, Oraxol, filed for Chapter 11 bankruptcy protection.
Jennifer Ann Kiggans (née Moore; born June 18, 1971) is an American politician, former United States Navy helicopter pilot, and geriatric nurse practitioner serving as the U.S. representative for Virginia's 2nd congressional district since 2023. A member of the Republican Party, she previously served in the Virginia Senate from 2020 to 2022. Kiggans was first elected to the House in 2022, defeating Democratic incumbent Elaine Luria. She was re-elected in 2024.
Sources: en.wikipedia.org
Tasmanian oak is a native Australian hardwood produced by any of three trees, Eucalyptus regnans, Eucalyptus obliqua or Eucalyptus delegatensis, when it is sourced from the Australian state of Tasmania. Despite the common name "oak", none of the species are in the genus Quercus or the oak family Fagaceae. The hardwood timber is light-coloured, ranging from straw to light reddish brown. It is used in construction, including panelling and flooring, for furniture, and also for reconstituted board and high quality paper. When sourced from Victoria, the wood of Eucalyptus regnans and Eucalyptus delegatensis is called Victorian ash. The species are also widely known by their common names. Eucalyptus obliqua is known as stringybark or messmate, Eucalyptus regnans is known as mountain ash, and the closely related Eucalyptus delegatensis is known as alpine ash or woollybutt.
=== Interviews and promotional press === Vulture published an interview with Clipse in which an album was explicitly confirmed, on June 19, 2024—one day after "The Birds Don't Sing" was previewed at the Louis Vuitton's Men's Spring–Summer Show 2025. Interviewed by Craig Jenkins, the duo reflected on the passing of their parents and how that experience, along with Williams's father dealing with dialysis treatments, influenced the lyrics of "The Birds Don't Sing". Pusha T revealed that Malice came up with the title, inspired by writer and activist Maya Angelou's 1969 autobiography I Know Why the Caged Bird Sings. Other topics included the brothers' father giving Malice his blessing to return to Clipse, the "coke rap" label often assigned to them, and Pusha T being referenced by Kendrick Lamar in his 2024 rap battle with Drake. Additionally, a comeback album was officially announced for the first time, although no title or release date was given. Pusha T stated: "The next year is going to be filled with appearances, touring, and a rap album of the year." Clipse spoke to Njera Perkins of People in an interview published on August 15, 2024. They talked about their then-upcoming performance at the Pepsi Dig In Day Block Party charity event, they joys of performing live in general, and how Williams had been pushing for a reunion.
Regarding the first part of the film, Barry White of Citizen Game commented, "Considering the comparatively paltry resources [...] at [the Purchase Brothers] disposal this short still manages to be better than every video game movie currently in existence." Wagner Au of NewTeeVee contended that the first part "is one of those rare viral videos that seems destined to launch a breakout success", and added "non-gamers are likely to be impressed by its rollicking action and bravura special effects." Au believed its popularity was due, in part, to the fact that the video is adapted from Half-Life 2. Patrick Goss, writing for TechRadar, said the in-game footage from the Half-Life 2 series "blended almost seamlessly into [the] live action footage" in the film. Valve, developers of the Half-Life series, approved of the film and publicized it in an announcement on Steam, saying "we were blown away – the production quality certainly exceeds that of the usual community-made movies we see."
== Biochemical structure == Kex2 was first purified and characterized by Charles Brenner and Robert Fuller in 1992. The Kex2 crystal structure was solved by a group led by Dagmar Ringe, Robert Fuller and Gregory Petsko. That of Furin was determined by a group led by Manual Than and Wolfram Bode. The key features of Kex2 and Furin are a subtilisin-related catalytic domain, a specificity pocket that requires the amino acid amino terminal to the scissile bond to be arginine for rapid acylation, and a P-domain carboxy-terminal to the subtilisin domain, which is required for biosynthesis.
== Use == The Tatra Shepherd Dog was traditionally used as a flock guardian dog, to deter predators from attacking flocks of sheep in the mountainous terrain of the Podhale region. In modern Poland it is most often kept either as a guard dog or as a companion animal.
Sources: en.wikipedia.org
Each freeze-thaw cycle can degrade a fraction of the peptide and promote aggregation. Dividing a stock solution into single-use volumes removes repeated cycling as a variable. It also limits the time a thawed solution spends at room temperature.
A high main-peak percentage says little about identity, counter-ion content, or residual solvents. It also does not distinguish an isomer or a closely eluting analog. Mass confirmation and the accompanying documentation cover those gaps.
Salt form changes mass, solubility, and hygroscopicity, and acetate and trifluoroacetate salts behave differently in solution. Storage guidance still centers on -20 °C for powder and lower temperatures for solutions. The certificate should state which salt is present.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.